Broadcast
FAX
DATE: August 11, 2015
TO: MnVFC Providers
FROM: MnVFC Program
RE: Meningococcal B Vaccines – Updated Recommendations
Please route to:
• Clinical supervisor
• Medical director
• Clinic manager
• Clinic staff
• Pharmacy
• Vaccine staff
In June 2015, the Advisory Committee on Immunization Practices (ACIP) released updated recommendations for the use
of the two licensed meningococcal B (MenB) vaccines: Bexsero and Trumenba.
ACIP Recommendations for MenB Vaccines
ACIP recommends meningococcal B vaccination of persons 10 years and older who are at increased risk for serogroup B
meningococcal disease. These include:
• Persistent complement component deficiencies
• Anatomic or functional asplenia
• Microbiologists exposed to isolates of N. meningitidis
• Identified at risk due to an outbreak of serogroup B meningococcal disease
Additionally, ACIP added that persons age 16 through 23 years may be vaccinated in order to receive short-term
protection against meningococcal B disease. The preferred age for MenB vaccination among adolescents is age 16
through 18 years. These recommendations have not yet been published.
Meningococcal B Vaccines
• There are two MenB vaccines - Bexsero (GSK) and Trumenba (Pfizer)
• Both products are licensed for persons age 10 through 25 years
• Bexsero is given as a 2-dose series 1 month apart
• Trumenba is given as a 3-dose series at intervals of 0, 2- and 6-months
Ordering Meningococcal B Vaccines
You can now order Bexsero and Trumenba from the MnVFC program through the Minnesota Immunization Information
Connection (MIIC) or on the paper order form. Since this is a new vaccine, we would encourage you to place smaller
initial orders to decrease the likelihood of vaccine wastage. Bexsero can be ordered in single-doses, if needed.
Vaccine Preventable Disease Section
625 N Robert Street * P.O. Box 64975 * St Paul, Minnesota 55164-0975
www.health.state.mn.us/vfc
M n V F C P R O G R AM : 6 51 - 2 0 1 - 55 2 2 o r 8 0 0 - 6 5 7 - 3 9 7 0